Wellington Management Group LLP Has $41.99 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Wellington Management Group LLP increased its holdings in Autolus Therapeutics PLC by 6.9% during the first quarter, owning approximately 10.18% of the company after acquiring over 1.74 million additional shares.
• Autolus Therapeutics reported a quarterly earnings per share of ($0.18), exceeding the consensus estimate of ($0.24) and generating $13.50 million in revenue, which was also above market expectations.
• Equities analysts have varying ratings on Autolus; Needham & Company reaffirmed a "buy" rating with a price target of $10.00, while Wells Fargo lowered its target from $6.00 to $5.00, indicating a mix of optimism and caution for investors.

Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 6.9% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 27,091,700 shares of the company's stock after buying an additional 1,746,020 shares during the period. Wellington Management Group LLP owned approximately 10.18% of Autolus Therapeutics worth $41,992,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Knott David M Jr bought a new stake in Autolus Therapeutics in the first quarter valued at about $651,000. Invesco Ltd. increased its stake in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after acquiring an additional 11,381 shares during the period. Privium Fund Management B.V. increased its stake in Autolus Therapeutics by 8.6% in the first quarter. Privium Fund Management B.V. now owns 251,674 shares of the company's stock valued at $390,000 after acquiring an additional 20,000 shares during the period. Cetera Investment Advisers increased its stake in Autolus Therapeutics by 47.3% in the first quarter. Cetera Investment Advisers now owns 524,872 shares of the company's stock valued at $814,000 after acquiring an additional 168,650 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in Autolus Therapeutics by 67.2% in the first quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company's stock valued at $108,000 after acquiring an additional 28,127 shares during the period. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Trading Down 4.5%

Shares of AUTL traded down $0.07 during mid-day trading on Friday, hitting $1.50. 2,140,325 shares of the company traded hands, compared to its average volume of 2,840,203. Autolus Therapeutics PLC Sponsored ADR has a one year low of $1.11 and a one year high of $5.00. The business has a 50-day moving average of $2.22 and a 200 day moving average of $1.86. The stock has a market capitalization of $399.21 million, a price-to-earnings ratio of -1.79 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million for the quarter, compared to the consensus estimate of $12.92 million. As a group, analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Needham & Company LLC reissued a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, July 21st. Finally, Wells Fargo & Company lowered their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Autolus Therapeutics has an average rating of "Buy" and an average price target of $9.12.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.